Erratum to: Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes

被引：0
|
作者：
Emily J. Gallagher
Zara Zelenko
Aviva Tobin-Hess
Ulrich Werner
Norbert Tennagels
Derek LeRoith
机构：
[1] Icahn School of Medicine at Mount Sinai,Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine
[2] Sanofi-Aventis Deutschland GmbH,Diabetes Research & Translational Medicine, Insulin Biology
来源：
Diabetologia | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：758 / 759
页数：1
相关论文
共 50 条
  • [21] The HND mouse, a nonobese model of type 2 diabetes mellitus with impaired insulin secretion
    Horio, F
    Teradaira, S
    Imamura, T
    Anunciado, RVP
    Kobayashi, M
    Namikawa, T
    Niki, I
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (06) : 971 - 979
  • [22] Assessment of Romanian Type 2 Diabetes patients treated with insulin glargine after failure of non-insulin therapy in daily clinical practice
    Guja, Cristian
    Botnariu, Gina
    Cerghizan, Anca
    Dinca, Mihaela
    Popa, Amorin
    Suciu, Gina
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S101 - S102
  • [23] Effect of human insulin on breast cancer risk in Taiwanese women with type 2 diabetes
    Tseng, Chin-Hsiao
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [24] The Stem Cell Mobilizer StemEnhance® Does Not Promote Tumor Growth in an Orthotopic Model of Human Breast Cancer
    Drapeau, Christian
    Ma, Huaiyu
    Yang, Zhijian
    Tang, Li
    Hoffman, Robert M.
    Schaeffer, David J.
    ANTICANCER RESEARCH, 2009, 29 (01) : 443 - 447
  • [25] Adipocyte-derived exosomes may promote breast cancer progression in type 2 diabetes
    Jafari, Naser
    Kolla, Manohar
    Meshulam, Tova
    Shafran, Jordan S.
    Qiu, Yuhan
    Casey, Allison N.
    Pompa, Isabella R.
    Ennis, Christina S.
    Mazzeo, Carla S.
    Rabhi, Nabil
    Farmer, Stephen R.
    Denis, Gerald, V
    SCIENCE SIGNALING, 2021, 14 (710)
  • [26] Erratum: How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?
    Jennifer B Marks
    Nature Clinical Practice Endocrinology & Metabolism, 2008, 4 : 702 - 702
  • [27] NON-INSULIN-DEPENDENT (TYPE 2) DIABETES-MELLITUS - DOES IT REALLY EXIST
    ZIMMET, P
    DIABETIC MEDICINE, 1989, 6 (08) : 728 - 735
  • [28] Thyroid hormone potentiates insulin signaling and attenuates hyperglycemia and insulin resistance in a mouse model of type 2 diabetes
    Lin, Yi
    Sun, Zhongjie
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 162 (03) : 597 - 610
  • [29] Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
    Sanjay Kalra
    Diabetes Therapy, 2017, 8 : 213 - 217
  • [30] Treatment with human insulin does not increase thyroid cancer risk in patients with type 2 diabetes
    Tseng, Chin-Hsiao
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2014, 44 (08) : 736 - 742
12345